VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Holdings in Pacira BioSciences, Inc. $PCRX

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 31,100 shares of the company’s stock, valued at approximately $743,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.07% of Pacira BioSciences at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of PCRX. Caitong International Asset Management Co. Ltd acquired a new stake in Pacira BioSciences during the 1st quarter worth $51,000. US Bancorp DE grew its holdings in Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after acquiring an additional 537 shares during the period. Brooklyn Investment Group grew its holdings in Pacira BioSciences by 372.2% during the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock worth $56,000 after acquiring an additional 1,764 shares during the period. Wealthquest Corp acquired a new stake in Pacira BioSciences during the 1st quarter worth $59,000. Finally, Strs Ohio acquired a new stake in Pacira BioSciences during the 1st quarter worth $75,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

PCRX has been the subject of a number of analyst reports. Truist Financial raised shares of Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a report on Friday, July 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pacira BioSciences in a report on Wednesday, October 8th. Finally, Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $33.40.

Insider Buying and Selling

In related news, Director Marcelo Bigal sold 4,912 shares of the business’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $23.67, for a total value of $116,267.04. Following the sale, the director directly owned 11,393 shares of the company’s stock, valued at approximately $269,672.31. The trade was a 30.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $21.74 on Friday. Pacira BioSciences, Inc. has a 12-month low of $16.00 and a 12-month high of $27.64. The firm has a market capitalization of $976.84 million, a price-to-earnings ratio of -7.82 and a beta of 0.40. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. The firm has a fifty day moving average of $25.08 and a 200-day moving average of $24.69.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The company had revenue of $181.10 million during the quarter, compared to analyst estimates of $183.11 million. During the same quarter in the previous year, the business earned $0.96 EPS. The firm’s revenue was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.